These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

786 related articles for article (PubMed ID: 12820960)

  • 1. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2.
    Garami A; Zwartkruis FJ; Nobukuni T; Joaquin M; Roccio M; Stocker H; Kozma SC; Hafen E; Bos JL; Thomas G
    Mol Cell; 2003 Jun; 11(6):1457-66. PubMed ID: 12820960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
    Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
    Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical and functional characterizations of small GTPase Rheb and TSC2 GAP activity.
    Li Y; Inoki K; Guan KL
    Mol Cell Biol; 2004 Sep; 24(18):7965-75. PubMed ID: 15340059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies.
    Shah OJ; Wang Z; Hunter T
    Curr Biol; 2004 Sep; 14(18):1650-6. PubMed ID: 15380067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.
    Kwiatkowski DJ
    Cancer Biol Ther; 2003; 2(5):471-6. PubMed ID: 14614311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.
    Inoki K; Li Y; Xu T; Guan KL
    Genes Dev; 2003 Aug; 17(15):1829-34. PubMed ID: 12869586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling.
    Tee AR; Fingar DC; Manning BD; Kwiatkowski DJ; Cantley LC; Blenis J
    Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13571-6. PubMed ID: 12271141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses.
    Smith EM; Finn SG; Tee AR; Browne GJ; Proud CG
    J Biol Chem; 2005 May; 280(19):18717-27. PubMed ID: 15772076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
    Nobukini T; Thomas G
    Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.
    Jaeschke A; Hartkamp J; Saitoh M; Roworth W; Nobukuni T; Hodges A; Sampson J; Thomas G; Lamb R
    J Cell Biol; 2002 Oct; 159(2):217-24. PubMed ID: 12403809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent.
    Karbowniczek M; Cash T; Cheung M; Robertson GP; Astrinidis A; Henske EP
    J Biol Chem; 2004 Jul; 279(29):29930-7. PubMed ID: 15150271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways.
    Gau CL; Kato-Stankiewicz J; Jiang C; Miyamoto S; Guo L; Tamanoi F
    Mol Cancer Ther; 2005 Jun; 4(6):918-26. PubMed ID: 15956249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.
    Castro AF; Rebhun JF; Clark GJ; Quilliam LA
    J Biol Chem; 2003 Aug; 278(35):32493-6. PubMed ID: 12842888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Turnover of the active fraction of IRS1 involves raptor-mTOR- and S6K1-dependent serine phosphorylation in cell culture models of tuberous sclerosis.
    Shah OJ; Hunter T
    Mol Cell Biol; 2006 Sep; 26(17):6425-34. PubMed ID: 16914728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cAMP inhibits mammalian target of rapamycin complex-1 and -2 (mTORC1 and 2) by promoting complex dissociation and inhibiting mTOR kinase activity.
    Xie J; Ponuwei GA; Moore CE; Willars GB; Tee AR; Herbert TP
    Cell Signal; 2011 Dec; 23(12):1927-35. PubMed ID: 21763421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TSC1/TSC2 and Rheb have different effects on TORC1 and TORC2 activity.
    Yang Q; Inoki K; Kim E; Guan KL
    Proc Natl Acad Sci U S A; 2006 May; 103(18):6811-6. PubMed ID: 16627617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
    Robb VA; Astrinidis A; Henske EP
    Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
    Zhang Y; Gao X; Saucedo LJ; Ru B; Edgar BA; Pan D
    Nat Cell Biol; 2003 Jun; 5(6):578-81. PubMed ID: 12771962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rheb fills a GAP between TSC and TOR.
    Manning BD; Cantley LC
    Trends Biochem Sci; 2003 Nov; 28(11):573-6. PubMed ID: 14607085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.
    Huang J; Manning BD
    Biochem J; 2008 Jun; 412(2):179-90. PubMed ID: 18466115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.